He also cited recent data from IPASS (IRESSA Pan-ASia Study) [3,4], comparing gefitinib with platinum-based doublet chemotherapy in advanced NSCLC, to demonstrate that predictive markers such as activating epidermal growth factor receptor (EGFR) mutations not only determine whether or not a particular intervention has a beneficial impact on conventional endpoints such as progression-free survival (PFS), but importantly on parameters such as quality of life (QoL) and symptom improvement. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.